Compare MRTN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRTN | PHAT |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.3M | 942.6M |
| IPO Year | 1986 | 2019 |
| Metric | MRTN | PHAT |
|---|---|---|
| Price | $12.64 | $14.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $19.00 | $17.33 |
| AVG Volume (30 Days) | 932.4K | ★ 1.4M |
| Earning Date | 01-23-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $903,976,000.00 | $147,190,000.00 |
| Revenue This Year | N/A | $220.82 |
| Revenue Next Year | $0.24 | $82.87 |
| P/E Ratio | $52.14 | ★ N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $9.35 | $2.21 |
| 52 Week High | $16.95 | $18.31 |
| Indicator | MRTN | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 66.51 | 44.76 |
| Support Level | $12.33 | $13.79 |
| Resistance Level | $13.00 | $16.12 |
| Average True Range (ATR) | 0.36 | 0.90 |
| MACD | 0.02 | -0.29 |
| Stochastic Oscillator | 80.64 | 24.34 |
Marten Transport Ltd is a temperature-sensitive truckload carrier in the United States. The company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. It operates through four segments: Truckload, Dedicated, Intermodal, and Brokerage, generating the majority of its revenue from the Truckload segment. The Truckload segment offers a mix of regional short-haul and medium- to long-haul full-load transportation services.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.